Kymera Therapeutics (NASDAQ:KYMR) Announces Quarterly Earnings Results

Kymera Therapeutics (NASDAQ:KYMR) posted its quarterly earnings data on Thursday. The company reported ($1.32) earnings per share for the quarter, missing the consensus estimate of ($1.26) by ($0.06), FiscalAI reports. Kymera Therapeutics had a negative net margin of 285.33% and a negative return on equity of 21.22%. During the same period in the prior year, the firm earned ($0.94) EPS. The business’s revenue was up .0% on a year-over-year basis.

Here are the key takeaways from Kymera Therapeutics’ conference call:

• KT-579 showed robust human proof of mechanism: once-daily dosing produced more than 90% IRF5 degradation in the top dose cohorts, including comparable effects in skin, with substantial reductions across inflammatory cytokine, interferon, and B-cell pathways.
• KT-579 was well tolerated in the phase I study, with a safety profile comparable to placebo, no serious adverse events, no discontinuations, and no infection imbalance. Kymera plans to advance the program into the approximately 30-patient LUMORA phase Ib lupus trial by early 2027.
• The company completed the 16-week placebo-controlled portion of the KT-621 BROADEN2 atopic dermatitis study and expects to report results by year-end; 98% of eligible patients entered the 52-week open-label extension. Kymera is preparing for a potential phase III AD study beginning by mid-2027, subject to supportive results and FDA alignment.
• KT-621 asthma enrollment is progressing as planned, with phase IIb BREADTH results expected in late 2027, while partner programs KT-485 and KT-200 also remain on track. Management emphasized potential expansion into additional type 2 inflammatory diseases, but detailed plans will depend on upcoming clinical data.
• Kymera ended September with approximately $1.6 billion in cash and investments, providing a projected runway into 2029 and funding planned KT-621 phase III preparations, the KT-579 lupus study, and continued pipeline research without near-term financing pressure.

Kymera Therapeutics Trading Up 0.1%

KYMR stock traded up $0.09 during midday trading on Thursday, reaching $122.60. 1,045,357 shares of the company traded hands, compared to its average volume of 831,641. The business has a 50 day moving average of $114.92 and a 200-day moving average of $95.84. Kymera Therapeutics has a 52-week low of $55.66 and a 52-week high of $130.05.

Analyst Ratings Changes

KYMR has been the topic of several research reports. Stifel Nicolaus lifted their price target on Kymera Therapeutics from $132.00 to $152.00 and gave the company a “buy” rating in a research report on Tuesday, September 22nd. Wolfe Research upgraded Kymera Therapeutics from a “peer perform” rating to an “outperform” rating and set a $180.00 target price on the stock in a research note on Thursday, September 10th. Raymond James Financial reissued an “outperform” rating on shares of Kymera Therapeutics in a report on Thursday. Oppenheimer reissued an “outperform” rating and issued a $140.00 target price on shares of Kymera Therapeutics in a report on Thursday. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Kymera Therapeutics in a research note on Thursday, October 15th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Kymera Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $137.32.

Kymera Therapeutics News Roundup

Here are the key news stories impacting Kymera Therapeutics this week:

• Positive Sentiment: KT-579 produced encouraging Phase 1 results. Kymera reported deep and sustained IRF5 degradation, strong changes in disease-relevant biomarkers and a favorable safety profile in healthy volunteers. The data support continued development of KT-579 for immunological diseases and were the most important positive catalyst in the update. Kymera Announces Third Quarter 2026 Financial Results and Reports Positive Results from the KT-579 Phase 1 Healthy Volunteer Trial
• Positive Sentiment: BTIG Research raised its price target to $139 from $134 and maintained a Buy rating. The revised target implies approximately 13.4% potential upside based on the referenced share price, signaling continued analyst confidence in Kymera’s pipeline and outlook. BTIG Research Kymera Ratings
• Neutral Sentiment: Management’s Q3 earnings call focused on the KT-579 results and broader pipeline progress. Investors are likely looking for additional details on development plans, upcoming milestones and the company’s financial resources; the available transcript listings do not provide further quantified guidance. Kymera Q3 2026 Earnings Call Transcript
• Negative Sentiment: Quarterly results were weaker than expected. Kymera reported a third-quarter loss of $1.32 per share versus the $1.26 consensus estimate, while the year-ago loss was $0.94 per share. Revenue was essentially unchanged year over year, and the company continued to report a deeply negative net margin, underscoring its ongoing reliance on clinical development funding. Kymera Reports Third Quarter and Nine-Month Earnings Results

Insider Activity at Kymera Therapeutics

In related news, insider Brian Adams sold 6,371 shares of the stock in a transaction on Friday, September 4th. The stock was sold at an average price of $116.83, for a total transaction of $744,323.93. Following the sale, the insider owned 50,254 shares in the company, valued at approximately $5,871,174.82. This represents a 11.25% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Nello Mainolfi sold 30,000 shares of Kymera Therapeutics stock in a transaction on Thursday, October 1st. The stock was sold at an average price of $113.80, for a total transaction of $3,414,000.00. Following the transaction, the chief executive officer directly owned 666,568 shares of the company’s stock, valued at $75,855,438.40. The trade was a 4.31% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 15.98% of the company’s stock.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical-stage biotechnology company focused on developing medicines that selectively eliminate disease-causing proteins through targeted protein degradation. Its approach is designed to use the cell’s natural protein-disposal system to remove proteins that may be difficult to address with conventional drug modalities.

The company’s research and development programs have targeted a range of disease areas, including immune-mediated and inflammatory conditions, cancer, and other serious illnesses.